SELLAS Life Sciences Group, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company has and reveals a legal setback that may affect future payments.
Changes to executive pay packages affect how much money leaders receive if the company is sold or they leave.
Investors voted to give the company more stock options to offer employees, which can dilute existing shareholders.
Shows the company raised cash when investors converted warrants into stock, improving financial position.
Quarterly earnings reports let investors see if the company is making progress or spending cash faster.
Detailed quarterly filing shows balance sheet, expenses, and business activities investors need to evaluate.
Annual results reveal whether the company grew revenue, managed costs, or deepened losses during the year.
Stocky reads SELLAS Life Sciences Group, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
SELLAS Life Sciences Group, Inc.'s most recent tracked filing was a 8-K on 27 Jul 2026: Company holds $138.3 million cash, loses arbitration with 3D Medicines.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.